Indication
Pancreatic Neuroendocrine Tumor
19 clinical trials
24 products
6 drugs
Clinical trial
A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR InhibitorsStatus: Recruiting, Estimated PCD: 2025-05-09
Product
nab-sirolimusClinical trial
Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA TherapyStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Product
EverolimusProduct
LanreotideProduct
RYZ101Product
SunitinibProduct
Octreotide LARProduct
BelzutifanClinical trial
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic AlterationsStatus: Recruiting, Estimated PCD: 2027-02-26
Clinical trial
AN OBSERVATIONAL REAL-WORLD STUDY OF THE SYSTEMIC TREATMENT OF WELL-DIFFERENTIATED, UNRESECTABLE OR METASTATIC, PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMOURS (PNET): A STUDY OF MORBIDITY AND MORTALITY AT 2 YEARSStatus: Completed, Estimated PCD: 2019-11-18
Product
everolimusProduct
sunitinibClinical trial
A Bioequivalence Study of Sunitinib Malate Capsules in Healthy Volunteers Under Fed Condition.Status: Completed, Estimated PCD: 2019-01-06
Product
Sunitinib malateProduct
CVM-1118Clinical trial
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients With Advanced Neuroendocrine TumorsStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine TumorsStatus: Recruiting, Estimated PCD: 2025-06-14
Product
Lutetium Lu 177 DotatateClinical trial
Evaluation of the Role of Proton Pump Inhibitors on the Postoperative Course Following PancreaticoduodenectomyStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Product
PlaceboProduct
PantoprazoleClinical trial
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)Status: Recruiting, Estimated PCD: 2025-06-30
Product
mRNA-0523-L001Clinical trial
A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)Status: Recruiting, Estimated PCD: 2025-09-30
Product
AbemaciclibClinical trial
Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine TumorsStatus: Not yet recruiting, Estimated PCD: 2026-11-29
Product
SurufatinibDrug
VarlilumabClinical trial
Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination With Ziv-Aflibercept (NSC# 724770) in Patients With Advanced CancersStatus: Completed, Estimated PCD: 2021-06-29
Product
SapanisertibProduct
Ziv-AfliberceptDrug
cyclophosphamideDrug
fludarabineClinical trial
An Open-Label, Phase II Study of Cabozantinib (XL184) in Advanced Pancreatic Neuroendocrine and Carcinoid TumorsStatus: Completed, Estimated PCD: 2021-08-01
Product
CabozantinibClinical trial
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine TumorsStatus: Recruiting, Estimated PCD: 2025-03-31
Drug
UTD1Product
TMZClinical trial
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)Status: Active (not recruiting), Estimated PCD: 2023-08-23
Clinical trial
Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine TumorsStatus: Recruiting, Estimated PCD: 2028-03-31
Drug
AN0025Clinical trial
A Phase II Multicenter Trial of ESK981 in Patients With Select Solid TumorsStatus: Recruiting, Estimated PCD: 2027-04-01
Product
ESK981Clinical trial
A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-09-30
Drug
Atezolizumab